Arrowhead Research | ARWR - Equity Capital And Reserves


Arrowhead Research reported $568.42M in Equity Capital and Reserves for its fiscal quarter ending in December of 2025.





Equity Capital And Reserves Change Date
Agios Pharmaceuticals USD 1.19B 91.22M Dec/2025
Alnylam Pharmaceuticals USD 789.18M 555.28M Dec/2025
Anika Therapeutics USD 143.46M 3.34M Dec/2025
Arrowhead Research USD 568.42M 102.37M Dec/2025
Heron Therapeutics USD 13.28M 1.6M Dec/2025
Incyte USD 5.17B 516.28M Dec/2025
Ionis Pharmaceuticals USD 617.97M 13.76M Sep/2025
Ligand Pharmaceuticals USD 1.02B 67.04M Dec/2025
Merck USD 51.85B 2.79B Sep/2025
Moderna USD 8.65B 680M Dec/2025
Nektar Therapeutics USD 89.83M 4.75M Dec/2025
Novartis USD 46.13B 1.38B Dec/2025
Sarepta Therapeutics USD 1.14B 179.5M Dec/2025
TG Therapeutics USD 648.02M 40.8M Dec/2025
Ultragenyx Pharmaceutical USD 9.16M 142.13M Sep/2025
Vertex Pharmaceuticals USD 18.67B 1.35B Dec/2025
Xencor USD 635.59M 10.27M Dec/2025